China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
One Percent Rule Checklist For Safer Forex Trading Risk 
LOS ANGELES, April 06, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceuticals Holdings LTD (“Kitov” or the “Company”) (Nasdaq:KTOV) concerning possible violations of federal securities laws. Investors who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), should contact the firm prior to the April 10, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel had been detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial. When this news information reached the investing public, Kitov’s stock price declined.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
